Introduction Assessing patient-specific risk factors for long-term mortality following resection of pancreatic adenocarcinoma can be difficult. Sarcopenia-the measurement of muscle wasting-may be a more objective and comprehensive patientspecific factor associated with long-term survival. Methods Total psoas area (TPA) was measured on preoperative cross-sectional imaging in 557 patients undergoing resection of pancreatic adenocarcinoma between 1996 and 2010. Sarcopenia was defined as the presence of a TPA in the lowest sex-specific quartile. The impact of sarcopenia on 90-day, 1-year, and 3-year mortality was assessed relative to other clinicopathological factors. Results Mean patient age was 65.7 years and 53.1 % was male. Mean TPA among men (611 mm . Surgery involved pancreaticoduodenectomy (86.0 %) or distal pancreatectomy (14.0 %). Mean tumor size was 3.4 cm; 49.9 % and 88.5 % of patients had vascular and perineural invasion, respectively. Margin status was R0 (59.0 %) and 77.7 % patients had lymph node metastasis. Overall 90-day mortality was 3.1 % and overall 1-and 3-year survival was 67.9 % and 35.7 %, respectively. Sarcopenia was associated with increased risk of 3-year mortality (HR01.68; P<0.001). Tumor-specific factors such as poor differentiation on histology (HR01.75), margin status (HR01.66), and lymph node metastasis (HR02.06) were associated with risk of death at 3-years (all P<0.001). After controlling for these factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR01.63; P<0.001). Conclusions Sarcopenia was a predictor of survival following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors.
Introduction
Pancreatic cancer is an aggressive malignancy and surgical resection is the only potentially curative treatment option with a 5-year survival ranging from 10 % to 20 %. [1] [2] [3] [4] [5] Traditionally one of the most complex abdominal operations, improvements in operative technique, and perioperative care over the past several decades have resulted in improved morbidity and mortality. Operative mortality has decreased to less than 5 % at high volume centers and morbidity has improved, but still remains high at 40-60 %. [6] [7] [8] In turn, high morbidity rates are associated with prolonged hospital stays, increased need for additional procedures or operations, and increased resource utilization. [9] [10] [11] Quality improvement measures have focused on improving outcomes and decreasing morbidity and mortality following high-risk procedures. In addition, prognosis following surgery for pancreatic cancer remains poor. While previous studies have examined prognosis following surgery, these studies have largely focused on tumor-specific clinicopathological factors such as lymph node metastasis, margin status, and tumor size, among others. [12] [13] [14] Prognosis following surgery is, however, undoubtedly multifactorial and is related not only to tumor-specific factors but also individual patient characteristics. The American Society of Anesthesiologist (ASA) classification, Eastern Cooperative Oncology Group (ECOG) performance status and body mass index (BMI)-among others-have been used with varying degrees of success, but often fail to identify those patients at highest risk for perioperative complications or mortality. Several groups have suggested the Estimation of Physiologic Ability and Surgical Stress Scoring (E-PASS) system as a more comprehensive physiologic estimation; however, results have been mixed. [15] [16] [17] Frailty, a measure believed to estimate a patient's physiologic reserves, has recently been proposed as a more robust predictor of outcomes following surgery. 18, 19 Initial assessments of frailty have been criticized for relying on scales dependent on subjective evaluations of weakness, exhaustion, and physical activity. Thus some investigators have proposed the use of sarcopenia-depletion of muscle mass as measured by cross-sectional imaging-as a more objective measure of frailty and, in turn, perhaps a better predictor of outcome. Previous data have suggested that sarcopenia may be associated with worse outcomes among patients being treated with chemotherapy for pancreatic, breast, prostate, and renal cell cancer. [20] [21] [22] [23] [24] [25] Only a few studies have examined the association between the presence of sarcopenia and outcomes following surgery. These studies have included patients undergoing surgery for melanoma, colorectal liver metastasis, and liver transplantation, but not pancreatic cancer. 19, 26, 27 Given the importance of assessing patientspecific risk factors for resection of pancreatic adenocarcinoma, we sought to investigate the impact of sarcopenia among patients undergoing resection for pancreatic adenocarcinoma. Specifically, we hypothesize that preoperative sarcopenia would lead to worse short-and long-term outcomes among patients undergoing surgery for pancreatic adenocarcinoma.
Methods

Patients and data collection
Between 1999 and 2010, 1,593 patients who underwent curative intent surgery for pancreatic cancer were identified from the Johns Hopkins Hospital pancreas database. Perioperative abdominal CT images (i.e., within 30 days of surgery) were available for re-review for 557 patients, representing the study cohort. Clinical and pathological data were collected including information on demographics, tumor stage, tumor size, operative details, length of ICU, and hospital stay. Data on perioperative morbidity and mortality were also collected. Complications were scored by ClavienDindo classification with major complications being defined as Clavien grade ≥3. 28 This study was approved by the Johns Hopkins Institutional Review Board.
Image Analysis
Sarcopenia was assessed by measuring the cross sectional area of the right and left psoas muscles (total psoas muscle area0TPA). TPA was measured at the level of L3 on the first image with both vertebral spines visible. Measurements were performed in a semi-automated fashion with manual outlining of psoas muscle borders and setting the density threshold between −30 and 110 Hounsfield Units (HU; Fig. 1 ). This allowed for automatic calculation of psoas muscle area by excluding vasculature and areas of fatty infiltration based on HU. The measured psoas area was then normalized for height, as per convention for body composition measurements (TPA mm 2 /m 2 ).
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Statistical analysis
Data are provided as mean, median, and standard deviation for continuous variables. The impact of sarcopenia was evaluated as both a continuous and categorical variable. Patients were stratified by quartiles according to TPA and sarcopenia was defined in the categorical analyses as the lowest quartile for men and women separately. The impact of sarcopenia on morbidity and mortality was examined using univariate and multivariate analyses. Overall survival was evaluated using the Kaplan-Meier method. A P value <0.05 was considered statistically significant. Statistical analyses were performed using Stata (Stata Corp, College Station, TX, USA).
Results
Demographic and Clinical Characteristics
The clinical and pathological characteristics of 557 patients included in the study are outlined in Table 1 . The average age of the study population was 65.7 years. There were 296 men (53.1 %) and 261 women (46.9 %) in the study population. Overall, the majority of tumors (71.5 %) were stage Age also tended to be associated with the incidence of sarcopenia as there was a trend toward decreasing TPA with increasing age (Fig. 2b) . Sarcopenia was noted across a wide range of BMIs. Sarcopenia was less frequently observed, however, among obese patients with a BMI≥30 kg/m 2 . Of the 112 patients who had a BMI ≥ 30 kg/m 2 , 15 (13.3 %) also had sarcopenia and therefore were characterized as having sarcopenic obesity. In contrast, among patients with a BMI≤24.9 kg/m 2 the incidence of sarcopenia was 36.2 %.
Impact of Sarcopenia
Of the 557 patients who underwent pancreatic resection, 260 experienced a least one complication for an overall morbidity of 46.6 %. The most common postoperative complications included wound complications (15 %), delayed gastric b Age tended to be associated with the incidence of sarcopenia as there was a trend toward decreasing TPA with increasing age emptying (15 %), and pancreatic fistula (8.5 %). Most complications were minor; 18.7 % of patients experienced a major (Clavien grade≥3) complication. The presence of sarcopenia was not associated with the risk of overall morbidity (OR00.88, 95 % CI 0.60-1.29; P00.51) or the risk of major complications (OR00.72, 95 % CI 0.43-1.21; P00.21; Table 2 ). Median ICU and overall length of hospital stay was similar among patients who had sarcopenia (ICU, 0.4 days; overall stay, 12.0 days) versus patients who did not have sarcopenia (ICU, 0.4 days; overall stay, 12.0 days) (P00.92 for ICU, P00.98 for length of stay).
There were 17 deaths within 90 days for a mortality of 3.1 %. Sarcopenia was not associated with increased hazard of 90-day death (HR02.31, 95 % CI 0.78-6.77; P00.13). For the entire cohort, the median overall survival was 14 months. Overall 1-and 3-year survival was 67.9 % and 35.7 %, respectively. Several factors were associated with survival at 3 years on univariate analysis including tumor size (HR01.13, 95 % CI 1.07-1.19), poor tumor differentiation (HR01.75, 95 % CI 1.40-2.12), vascular invasion (HR01.57, 95 % CI 1.27-1.93), as well as lymph node metastasis (HR02.06, 95 % CI 1.55-2.74; all P<0.001). The presence of sarcopenia was also associated with the risk of death at 3 years (HR 01.68, 95 % 1.34-2.11; P<0.001; Fig. 3 ). Deaths within the first 3 years of operation were found to be highest among patients in the lowest TPA quartile for both men (no sarcopenia, 60.8 % vs. sarcopenia, 79.7 %) and women (no sarcopenia, 59.2 % vs. sarcopenia, 73.9 %; both P<0.05). This translated into a worse 3-year survival for both men (no sarcopenia, 39.2 % vs. sarcopenia, 20.3 %) and women (no sarcopenia, 40.8 % vs. sarcopenia, 26.1 %; both P<0.05). On multivariate analysis, after controlling for tumor-specific factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR01.63, 95 % CI 1.28-2.07; P<0.001; Table 3 ).
Discussion
Advances in operative technique and perioperative care have improved outcomes following pancreatic surgery; however, surgical morbidity and mortality are still a concern. In addition, prognosis following surgery for pancreatic cancer remains poor. Studies examining prognosis following surgery have traditionally focused on tumor-specific clinico-pathological factors. For example, data from our group and others have noted that lymph node metastasis and margin status-among other factors-are associated with a worse prognosis following resection of pancreatic cancer. [12] [13] [14] Prognosis following surgery is, however, undoubtedly multifactorial and is related not only to tumorspecific factors but also individual patient characteristics. While several scoring systems have been proposed, their prognostic accuracy in quantifying the risk associated with patient-level physiological/performance status has been questioned. [15] [16] [17] Frailty has been proposed as a more global metric of patient physiological reserve and overall health status. 32 Frailty can be assessed utilizing patient questionnaires or varied clinical measurements of weakness or physical activity. 19, 32 These measurements can be nonreproducible and subject to measurement or reporting bias. More recently, sarcopenia-as assessed by the measurement of muscle mass on cross-sectional imaging-has been reported to be an accurate and quantitative marker of frailty. 19, 27, 32 The current study is important because we examined the prognostic impact of sarcopenia among a large cohort of patients who underwent pancreatic resection for pancreatic carcinoma. Specifically, we noted that sarcopenia was an independent predictor of mortality following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. As such, sarcopenia may be an important objective measure of patient frailty that can predict long-term outcome independent of tumor-specific factors. While it would be premature to advocate the use of sarcopenia as a factor to dictate postoperative therapy, similar to other important prognostic factors such as margin and node status, as well as T-stage, sarcopenia can assist in the risk stratification of patients in the postoperative period.
Sarcopenia is distinct from cancer related cachexia. 33, 34 Cancer patients often experience weight loss due to chemotherapy, symptoms from gastrointestinal malignancies, or Fig. 3 The presence of sarcopenia was also associated with the risk of death (no sarcopenia, 18.0 months; 40.0 % vs. sarcopenia, 13.7 months; 23.0 % median, 3-year survival, respectively; P00.01) cancer cachexia syndrome. Research in cancer cachexia has identified an association with endogenous transmitters and inflammatory markers which contribute to a negative nitrogen balance, fatigue, and weight loss. 35, 36 While weight remains an important measurement of nutritional status, various data have shown that there is differential loss of body fat and muscle in cancer cachexia. 37 Recent studies have begun to focus on muscle mass measurements as a better predictor of outcome in cancer patients undergoing chemotherapy and operative resection. Sarcopenia refers specifically to muscle loss and is associated with normal aging and non-oncologic disease states. [38] [39] [40] More recently, investigators have begun to examine the association between sarcopenia and outcomes among cancer patients receiving chemotherapy and have shown that sarcopenia is associated with worse outcomes among patients treated with chemotherapy for pancreatic, breast, prostate, and renal cell cancer. [21] [22] [23] [24] [25] The prognostic association of sarcopenia with surgical outcomes is less defined. While a few studies have noted an association with sarcopenia and worse outcomes among patients undergoing surgery for melanoma, colorectal liver metastases, and hepatocellular carcinoma, 19, 26, 27 the impact of sarcopenia on patients undergoing pancreatic surgery had not been examined prior to the current study.
The impact of sarcopenia on surgical morbidity remains ill defined. In our previous work, we had reported on the effect of sarcopenia among 259 patients who underwent liver resection for colorectal liver metastasis. 19 In that study, we noted that patients with sarcopenia had longer hospital stays, a higher chance of extended ICU stay, and an increased risk of postoperative complications. In contrast, in the current study we did not find that sarcopenia impacted length of stay or morbidity among a much larger (n0557) cohort of patients undergoing pancreatic resection of carcinoma. In fact, the presence of sarcopenia was not associated with the risk of either overall morbidity or the risk of major complications (Table 2 ). This finding was somewhat surprising, as one might have expected sarcopenia to be associated with a worse short-term outcome. The reason for the discrepancy regarding the impact of sarcopenia on morbidity in our two studies is not clear. Given that the two study populations were divergent, our collective data may suggest that the impact of sarcopenia on morbidity may be a function of the underlying patient population and cancer being studied.
In the current study, we noted a strong association between sarcopenia and survival. Similar to previously reported data, we found that tumor-specific factors such as lesion size, tumor differentiation, presence of vascular invasion, and lymph node metastasis were associated with survival. More importantly, however, was the finding that sarcopenia remained an independent predictor of survival even after controlling for these risk factors. In fact, at 3 years patients with sarcopenia had a greater than 60 % increased risk of death compared with patients who did not have sarcopenia (Fig. 3) . Englesbe et al. reported on the effect of sarcopenia on long-term mortality among patients undergoing liver transplantation. 27 The authors similarly noted that 3-year survival following transplantation was only 26 % among patients with sarcopenia versus 77 % among patients without sarcopenia-a threefold increase in sarcopenia-associated mortality risk. 27 In a separate study, Van Vledder et al. noted a near twofold decrease in 3-year survival among patients liver resection of colorectal liver metastasis who had sarcopenia (34.0 %) versus those patients who did not have sarcopenia (64.6 %). 32 Taken together, our data corroborate and validate the importance of sarcopenia as a valuable preoperative tool to risk stratify patients with regard to prognosis and survival.
Several limitations must be born in mind when considering our study. Similar to our previous work, we were not able to capture data on other frailty parameters such as grip strength, walking speed, or levels of exhaustion due to the study's retrospective design. 19 Despite having a large number of patients in the Johns Hopkins Hospital pancreatic database, many patients had cross-sectional imaging performed at an outside institution and therefore were not available for re-review. While these patients were not included in our analyses, it is likely that these data were missing/excluded at random and therefore did not pose a threat of selection bias. It was somewhat surprising that sarcopenia was not associated with short-term outcome. At very high volume centers such as Johns Hopkins, overall mortality following pancreatic surgery is a rare event (n0 17). Therefore, despite having a cohort size that was considerably larger than previous reports on the topic, the assessment of perioperative death and sarcopenia may have been susceptible to a type II error, especially if the effect was small. The interplay of frailty, sarcopenia and outcomes is undoubtedly complex and warrants future investigation. Finally, while we chose to utilize the psoas muscle-only approach to quantity sarcopenia in conjunction with BMI to quantify obesity, other approaches have been advocated. 41 In conclusion, surgical resection of pancreatic adenocarcinoma remains the mainstay of treatment for those patients with potentially resectable disease. While much attention has been paid in the surgical literature to tumor-specific factors that may be associated with prognosis, other patient-centered factors have not received as much attention. In the current study, we report that measurement of muscle mass can be obtained from preoperative cross-sectional imaging and that loss of this muscle mass-defined as sarcopenia-was associated with a 60 % increased risk of mortality at 3 years. Similar to postoperative tumor-specific metrics of prognosis, pre-operative assessment of sarcopenia may be an important independent tool to inform clinical decision-making and assist in risk stratification of patients with carcinoma undergoing pancreatic surgery.
